CAR T-Cell Therapy

Chimeric Antigen Receptor (CAR) T-Cell therapy is a type of cancer treatment in which patients’ T-cells are taken from their blood and altered in a laboratory to attack cancer cells.

T-cells are a type of immune system cell. The process of CAR T-Cell therapy adds a chimeric antigen receptor (CAR) to the cell, which allows the modified T-cell to recognize and attack cancer cells. Altered T-cells are given to the patient via infusion. The team at the Joseph M. Sanzari Children’s Hospital has been certified by Novartis Pharmaceuticals to treat patients with treatment-resistant acute lymphoblastic leukemia (ALL) using the first CAR T-Cell therapy, Kymriah. It is geared toward ALL patients who have refractory disease or have relapsed.

CAR T-Cell Therapy

The majority of patients who have been treated with CAR T-Cell therapy have experienced long-term remission as a result. As the only certified center to offer CAR T-Cell therapy to pediatric patients in New Jersey, the Pediatric Stem Cell Transplantation and Cellular Therapy Program at the Joseph M. Sanzari Children’s Hospital provide cutting-edge solutions that bring hope for a cure to patients for whom a cure was once thought to be impossible.

This can’t be done without you

Tackle Kids Cancer is a team effort. By raising awareness and funds, we help hundreds of pediatric patients being treated today, and help fund discoveries to keep children healthy in the future.


Children with cancer need your help. Your donation will save lives.